Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 22, 2015 08:30 ET | Source: Cellectar Biosciences, Inc.

Peer-Reviewed Glioma Surgery Study With Cellectar Biosciences Fluorescence Cancer-Targeting Agents Chosen for the Cover of Neurosurgery

MADISON, Wis., Jan. 22, 2015 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of...
January 09, 2015 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present at the Biotech Showcase 2015 Conference

MADISON, Wis., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of...
December 04, 2014 16:05 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Granted Orphan Designation for I-131-CLR1404 for the Treatment of Multiple Myeloma

MADISON, Wis., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of...
November 25, 2014 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Names Cameron Szakacs, Ph.D. Vice President of Clinical Development

MADISON, Wis., Nov. 25, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), announced the appointment of Cameron Szakacs, Ph.D., as vice president of clinical development. Dr. Szakacs...
November 11, 2014 16:05 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Reports Third Quarter 2014 Financial Results and Recent Highlights

MADISON, Wis., Nov. 11, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of...
November 06, 2014 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Host Conference Call on November 11th to Discuss Third Quarter 2014 Results and Provide Quarterly Update on Development Progress

MADISON, Wis., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of...
October 15, 2014 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces Publication of Findings Demonstrating Efficacy of Its Phospholipid Ether Analog Platform in Detecting Colorectal Cancer

MADISON, Wis., Oct. 15, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), announced that an article reporting the efficacy of its proprietary phospholipid ether (PLE) analog agents...
September 05, 2014 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces Participation in Two Upcoming Investor Conferences in September

Rodman & Renshaw 16th Annual Global Investment Conference on September 9, 2014 Aegis Capital 2014 Healthcare and Technology Conference on September 11, 2014 Webcasts Available Through...
September 04, 2014 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces Acceptance of Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed or Refractory Multiple Myeloma

MADISON, Wis., Sept. 4, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), announced today that the U.S. Food & Drug Administration (FDA) has accepted the Company's...
August 20, 2014 16:15 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Reports Second Quarter 2014 Financial Results and Recent Highlights

MADISON, Wis., Aug. 20, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of...